世界の癌治療用キナーゼ阻害剤市場:Brc-Abl阻害剤/EGFR阻害剤/血管新生阻害剤/BRAF・MEK阻害剤/mTOR阻害剤など...市場調査レポートについてご紹介

【英文タイトル】Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1. Report Overview
1.1 Overview of the World Market for Those Medicines
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQ)
1.8 Some Associated Reports
1.9 About Visiongain

2. Introduction to Anti-Cancer Kinase Inhibitors
2.1 What are Protein Kinases?
2.2 Protein Kinases in Oncology
2.3 Mechanisms for Kinase Inhibition
2.4 Glossary of Terms

3. Anti-Cancer Kinase Inhibitors: World Market 2014-2024
3.1 The Global Market for Anti-Cancer Kinase Inhibitors in 2013
3.1.1 Leading Anti-Cancer Kinase Inhibitors by Sales, 2013
3.1.2 Leading Companies in the Protein Kinase Inhibitor Market
3.2 World Protein Kinase Inhibitors for Oncology Market: Sales Forecast by Class, 2014-2024
3.2.1 Changing Market Shares by Segment 2014-2024
3.2.2 Leading Anti-Cancer Kinase Inhibitors Manufacturers, 2014-2024
3.3 Bcr-Abl Inhibitors Lead the Protein Kinase Inhibitors for Oncology Market in 2013
3.3.1 Bcr-Abl Kinase Inhibitors: Drivers and Restraints 2014-2024
3.4 Imbruvica and Other Novel Kinase Inhibitors Will Eventually Dominate the Market
3.4.1 Other Kinase Inhibitors: Drivers and Restraints, 2014-2024

4. Leading National and Regional Markets, 2014-2024
4.1 Regional Breakdown of the World Protein Kinase Inhibitors for Drugs Treating Cancer
4.2 World Protein Kinase Inhibitors for Oncology Market: Regional Forecast 2014-2024
4.2.1 How Will Regional Market Shares Change Through to 2024?
4.3 The US Anti-Cancer Kinase Inhibitor Market Forecast, 2014-2024
4.4 The US Market: Drivers and Restraints, 2014-2024
4.5 The EU Union Anti-Cancer Kinase Inhibitors Market Forecast, 2014-2024
4.5.1 EU Market: Drivers and Restraints
4.5.2 German Market Forecast, 2014-2024
4.5.3 French Market Forecast, 2014-2024
4.5.4 Italian Market Forecast, 2014-2024
4.5.5 UK Market Forecast, 2014-2024
4.5.6 Spanish Market Forecast, 2014-2024
4.6 The Japanese Anti-Cancer Kinase Inhibitor Market Forecast, 2014-2024
4.7 Forecasting Anti-Cancer Kinase Inhibitor Markets in Developing Countries, 2014-2024
4.7.1 Chinese Market Forecast, 2014-2024
4.7.2 Brazilian Market Forecast, 2014-2024
4.7.3 Russian Market Forecast, 2014-2024
4.7.4 Indian Market Forecast, 2014-2024

5. Leading Anti-Cancer Kinase Inhibitors Products, 2014-2024
5.1 Brc-Abl Inhibitors – Managed Care for Chronic Myeloid Leukaemia
5.1.1 Gleevec (imatinib) – Novartis
5.1.1.1 Historic Sales Performance
5.1.1.2 Lifecycle Management, Generic Challenges and Tasigna
5.1.1.3 Gleevec Forecast, 2014-2024
5.1.2 Sprycel (dasatanib) – Bristol-Myers Squibb
5.1.2.1 Patents and Market Exclusivity
5.1.2.2 Historic Sales Performance
5.1.2.3 Sprycel Forecast, 2014-2024
5.1.3 Tasigna (nilotinib) – Novartis
5.1.3.1 Indications and Market Exclusivity
5.1.3.2 Historic Sales Performance
5.1.3.3 Tasigna Forecast, 2014-2024
5.1.4 Bosulif (bosutinib) – Pfizer
5.1.4.1 Bosulif Forecast, 2014-2024
5.1.5 Iclusig (ponatinib) – ARIAD Pharmaceuticals
5.1.5.1 Iclusig Forecast, 2014-2024
5.2 EGFR Inhibitors
5.2.1 Tarceva (erlotinib) – Roche/Astellas
5.2.1.1 Patent Litigation and Market Exclusivity
5.2.1.2 Historic Sales Performance, 2004-2012
5.2.1.3 Tarceva Forecast, 2014-2024
5.2.2 Iressa (gefitinib) – AstraZeneca
5.2.2.1 Historic Sales Performance, 2003-2012
5.2.2.2 Iressa Forecast, 2014-2024
5.2.3 Gilotrif (afatinib) – Boehringer Ingelheim
5.2.3.1 Gilotrif Forecast, 2014-2024
5.3 Angiogenesis Inhibitors
5.3.1 Nexavar (sorafenib) – Bayer/Onyx
5.3.1.1 Historic Sales Performance, 2006-2012
5.3.1.2 Nexavar Forecast, 2014-2024
5.3.2 Sutent (sunitinib) – Pfizer
5.3.2.1 Historic Sales Performance, 2006-2012
5.3.2.2 Sutent Forecast, 2014-2024
5.3.3 Votrient (pazopanib) – GSK
5.3.3.1 Historic Sales Performance, 2010-2012
5.3.3.2 Votrient Forecast, 2014-2024
5.3.4 Inlyta (axitinib) – Pfizer
5.3.4.1 Inlyta Forecast, 2014-2024
5.4 BRAF and MEK Inhibitors
5.4.1 Zelboraf (vemurafenib) – Roche/Daiichi Sankyo
5.4.1.1 Zelboraf Forecast, 2014-2024
5.4.2 Mekinist (trametinib) and Tafinlar (dabrafenib) – GSK
5.4.2.1 Mekinist Forecast, 2014-2024
5.4.2.2 Tafinlar Forecast, 2014-2024
5.5 mTOR Inhibitors
5.5.1 Afinitor (everolimus) – Novartis
5.5.1.1 Patents and Market Exclusivity
5.5.1.2 Historic Sales Performance
5.5.1.3 Afinitor Forecast, 2014-2024
5.5.2 Torisel (temsirolimus) – Pfizer
5.5.2.1 Torisel Forecast, 2014-2024
5.6 Other leading Anticancer Kinase Inhibitors
5.6.1 Imbruvica (ibrutinib) –J&J/Pharmacyclics
5.6.1.1 Imbruvica Forecast, 2014-2024
5.6.2 Jakafi (ruxolitinib) – Novartis/Incyte
5.6.2.1 Jakafi Forecast, 2014-2024
5.6.3 Xalkori (crizotinib) – Pfizer
5.6.3.1 Xalkori Forecast, 2014-2024
5.6.4 Cometriq (cabozantinib) – Exelixis
5.6.4.1 Cometriq Forecast, 2014-2024
5.6.5 Caprelsa (vandetanib) – AstraZeneca
5.6.5.1 Caprelsa Forecast, 2014-2024
5.6.6 Tykerb (lapatinib) – GSK
5.6.6.1 Historic Sales Performance, 2007-2012
5.6.6.2 Tykerb Forecast, 2014-2024
5.6.7 Stivarga (regorafenib) – Bayer
5.6.7.1 Stivarga Forecast, 2014-2024

6. Anti-Cancer Kinase Inhibitors: R&D Pipeline, 2014-2024
6.1 Cyclin-Dependent Kinase 4/6 Inhibitors in Development
6.1.1 Palbociclib – Pfizer
6.1.1.1 Palbociclib Forecast, 2014-2024
6.1.2 LEE-011 – Novartis
6.1.2.1 LEE-011 Forecast, 2014-2024
6.1.3 Bemaciclib (LY2835219) – Eli Lilly
6.1.3.1 Bemaciclib Forecast, 2014-2024
6.2 Anaplastic Lymphoma Kinase (ALK) Inhibitors In Development
6.2.1 Alectinib – Roche
6.2.1.1 Alectinib Forecast, 2014-2024
6.2.2 Ceritinib (LDK378) – Novartis
6.2.2.1 Ceritinib Forecast, 2014-2024
6.2.3 AP26113 – ARIAD
6.3 Bruton’s Tyrosine Kinase and PI3K Inhibitors in Development
6.3.1 Idelalisib – Gilead
6.3.1.1 Idelalisib Forecast, 2014-2024
6.3.2 RG7601 (ABT-199) – Roche/AbbVie
6.3.2.1 ABT-199 Sales Forecast, 2014-2024
6.3.3 IPI-145 – Infinity Pharmaceuticals
6.3.3.1 IPI-145 Forecast, 2014-2024
6.3.4 Buparlisib (BKM120) – Novartis
6.3.4.1 Buparlisib Forecast, 2014-2024
6.3.5 ONO-4059 – Ono Pharmaceuticals
6.3.6 Copanlisib (BAY 80-6946) – Bayer
6.3.7 Pictilisib (GDC-0941) – Roche
6.3.8 BEZ235 – Novartis
6.4 MEK and BRAF Inhibitors in Development
6.4.1 Cobimetinib (GDC-0973) – Roche
6.4.1.1 Cobimetinib Forecast, 2014-2024
6.4.2 Encorafenib (LGX818) – Novartis
6.4.3 Binimetinib (MEK162) – Novartis
6.4.4 Selumetinib (AZD 6244) – AstraZeneca
6.5 Other Kinase Inhibitors in Development
6.5.1 Volasertib – Boehringer Ingelheim
6.5.1.1 Volasertib Forecast, 2014-2024
6.5.2 Neratinib (PB272) – Puma Biotechnology
6.5.3 Tivantinib (ARQ197) – Daiichi Sankyo
6.5.4 Dovotinib (TKI258) – Novartis
6.5.5 Dacomitinib – Pfizer
6.5.6 CO-1686 – Clovis Oncology

7. Qualitative Analysis of the Anti-Cancer Kinase Inhibitor Market, 2014-2024
7.1 SWOT Analysis of the Protein Kinase Inhibitors for Oncology Market
7.2 Strengths
7.2.1 Oral Dosage Preferred Over Injection
7.2.2 Stratifying Patients Offers Clinical and Commercial Benefits
7.2.3 Targeted Kinase Inhibitor are Generally Well Tolerated
7.2.4 A Strong Pipeline of Novel Inhibitors Will Drive Market Growth
7.3 Weaknesses
7.3.1 Small Molecule Kinase Inhibitors Will Experience Generic Competition
7.3.2 Competitor Biologics Offer Differentiated Mechanisms of Action
7.3.3 Monoclonal Antibodies are More Specific than Small Molecules
7.4 Opportunities
7.4.1 Novel Targets Identified Through Cancer Genomics
7.4.2 Combination Therapies Bring Additive Benefits
7.4.3 Commercial Success Leveraged by Clinical Benefit
7.5 Threats
7.5.1 Small Molecules Generics Are Easy to Produce
7.5.2 Individual Kinase Targets are Rapidly Becoming Crowded
7.6 STEP Analysis of the Protein Kinase Inhibitors for Oncology Market
7.7 Porter’s Five Forces Analysis of the Anti-Cancer Kinase Inhibitor Market, 2014-2024
7.7.1 Rivalry Among Competitors
7.7.2 Threat of New Entrants
7.7.3 Power of Suppliers
7.7.4 Power of Buyers
7.7.5 Threat of Substitutes

8. Research Interview
8.1 Interview with Dr Lawrence Bloch, Chief Finance and Business Officer, Infinity Pharmaceuticals, United States
8.1.1 Positioning a Novel Therapeutic in Blood Cancer Indications
8.1.2 Combining Therapies Offers Significant Benefit to Patients
8.1.3 Potential in Rheumatoid Arthritis and Blood Cancers

9. Conclusions
9.1 The Global Anti-Cancer Kinase Inhibitors Market to 2024
9.1.1 A Robust Pipeline of Innovative Drugs Driving Market Growth
9.2 Leading National Markets for Anti-Cancer Kinase Inhibitors to 2024


【レポート販売概要】

■ タイトル:世界の癌治療用キナーゼ阻害剤市場:Brc-Abl阻害剤/EGFR阻害剤/血管新生阻害剤/BRAF・MEK阻害剤/mTOR阻害剤など
■ 英文:Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024
■ 発行日:2014年6月
■ 調査会社:visiongain
■ 商品コード:VISG409052
■ 調査対象地域:グローバル
  • 靴乾燥機の世界市場2017-2021
    About Shoe Dryer Shoe dryers are used not only by the individuals but also by the gym and fitness clubs. Additionally, there has been an increase in the participation in the adventure sports across the globe. People go for hiking, fishing, trekking and skiing, and other such adventures where there are chances of the shoes getting wet. The manufacturers have also designed portable shoe dryers for s …
  • ペースメーカーの世界市場分析:製品別(埋め込み、外部)、地域別(北アメリカ(米国、カナダ)、ヨーロッパ(イギリス、ドイツ)、アジア太平洋(日本、中国)、ラテンアメリカ(ブラジル、メキシコ)、MEA(南アフリカ、サウジアラビア)}、セグメント予測、2014-2025
    The global pacemaker market is expected to reach USD 12.3 billion by 2025, according to a new report by Grand View Research, Inc. The heightening prevalence of cardiac conditions coupled with the availability of medical coverage is a key driving factor governing the growth of Pacemaker globally. In addition, technological enhancements in these devices are supporting the expansion of this vertical. …
  • 産業用Vベルトの世界市場2017-2021
    ABSTRACTAbout Industrial V-Belts Industrial V-belts are the basic belts for power transmission that is applied in light-weight to heavy-weight industrial applications. They are used as a source to provide power transmission efficiently. Industrial V-belts provide more friction and power and are installed in all end-user orientations for efficient machinery functions. Industrial V-belts are an inte …
  • 世界の防火装置市場2015
    The Global Fire Protection Equipment Industry Report 2015 is a professional and in-depth study on the current state of the Fire Protection Equipment industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Fire Protection Equipment market analysis is provided for the international markets including developm …
  • チロシンキナーゼ阻害剤の世界市場及びパイプラインインサイト
    Tyrosine kinase is a sub class of Protein Kinases family of enzyme responsible for phosphorylation.It has been found that mutation or other anomaly in these enzymes causes uncontrolled cell division leading to cancer. Because of their direct involvement in cell division they are used in cancer treatment by using kinase inhibitors to prevent unregulated cellular proliferation. Epidermal Growth Fact …
  • 2014年戦略提言:イタリアの血液及びフローサイトメトリー市場
    Complete report $6,200.  DataPack (test volumes, sales forecasts, supplier shares) $3,900.SummaryThis comprehensive report contains 250 pages, 32 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in Italian hematology and flow cytometry markets during the next five years.  The report explores business and …
  • Hemoglobinuria:グローバル臨床試験レビューH2, 2013
    Hemoglobinuria Global Clinical Trials Review, H2, 2013 Summary GlobalData's clinical trial report, “Hemoglobinuria Global Clinical Trials Review, H2, 2013" provides data on the Hemoglobinuria clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hemoglobinuria. It includes an overview of the trial numbers and their recruitment status as per …
  • 電子設計自動化(EDA)の世界市場2016-2020
    About EDA EDA comprises software tools used in the designing of electronic systems and components such as ICs and PCBs. The tools allow electrical (hardware) and computer (software) engineers to design, analyze, and simulate electronic components and systems. They are also used to derive methodologies and algorithms that aid in the designing of ultra-large-scale integration (ULSI) circuits. Segmen …
  • 薄膜・プリンテッドバッテリーの世界市場予測(~2022年)
    “Global thin film and printed battery market to exhibit significant growth potential between 2016 and 2022”The thin film and printed battery market is expected to grow at a CAGR of 24.7% between 2016 and 2022 to reach USD 1.25 billion by 2022. The key driving factors for the growth of the thin film and printed battery market are the increasing demand for wearable devices, increasing integration of …
  • クラスター弾の世界市場2016-2020
    About Cluster Munitions A cluster munition is an air-dropped or ground-launched explosive weapon that ejects smaller submunitions. Cluster bombs release explosive projectiles, which are designed to destroy vehicles, disperse chemical or biological weapons, scatter landmines, and kill personnel. These cluster bombs release many small munitions over a wide area, posing risks to civilians both during …
  • Alopecia:グローバル臨床試験レビューH1, 2013
    Alopecia Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, “Alopecia Global Clinical Trials Review, H1, 2013" provides data on the Alopecia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Alopecia. It includes an overview of the trial numbers and their recruitment status as per the site of trial condu …
  • 世界のLLDPE(直鎖状低密度ポリエチレン)市場2015
    The Global Linear Low Density Polyethylene Industry Report 2015 is a professional and in-depth study on the current state of the Linear Low Density Polyethylene industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Linear Low Density Polyethylene market analysis is provided for the international markets …
  • 代用骨移植片:企業と競争環境
    MediPoint: Bone Grafts and Substitutes - Current and Future Players Summary Although autograft is still perceived as the gold-standard material in bone grafting, the wide array of alternatives available in the market has resulted in a gradual shift towards increased adoption of bone grafts and substitutes (BGS), especially in the US and European markets. In contrast to the general picture in devel …
  • 産業用スケール抑制剤の世界市場2016-2020
    About the Industrial Anti-Scaling Chemicals Market The global industrial anti-scaling chemicals market is driven by the increasing demand from key end-uses including the oil, gas, and mining and water and wastewater treatment industries. The rapid growth of these industries in leading regions such as APAC, Central and South America, and Africa will be a key contributing factor. Anti-scaling chemic …
  • HVDC(高圧直流送電)システムの世界市場:相整流変換器(LCC)、キャパシタ整流変換器(CCC)、電圧型コンバータ(VSC)
    HVDC transmission system is basically environment-friendly because improved energy transmission possibilities contribute to a more efficient utilization of existing power plants. The ever increasing demand of electricity has laid enormous pressures on the present infrastructure of the power generation capacity. HVDC systems can transmit more electrical power over longer distances than a similar al …
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。